These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24060485)

  • 1. Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis?
    Thiele M; Wiest R; Gluud LL; Albillos A; Krag A
    Med Hypotheses; 2013 Nov; 81(5):871-4. PubMed ID: 24060485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective β-blockers.
    Madsen BS; Havelund T; Krag A
    Adv Ther; 2013 Jul; 30(7):659-70. PubMed ID: 23881723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials.
    Thiele M; Albillos A; Abazi R; Wiest R; Gluud LL; Krag A
    Liver Int; 2015 Aug; 35(8):2009-16. PubMed ID: 25581713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.
    Reiberger T; Ferlitsch A; Payer BA; Mandorfer M; Heinisch BB; Hayden H; Lammert F; Trauner M; Peck-Radosavljevic M; Vogelsang H;
    J Hepatol; 2013 May; 58(5):911-21. PubMed ID: 23262249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study.
    La Mura V; Abraldes JG; Berzigotti A; Erice E; Flores-Arroyo A; García-Pagán JC; Bosch J
    Hepatology; 2010 Jun; 51(6):2108-16. PubMed ID: 20512998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
    Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Complications of liver cirrhosis: oesophageal varices, ascites and hepato-cellular carcinoma].
    Troillet FX; Halkic N; Froehlich F; Moradpour D; Gonvers JJ; Denys A
    Rev Med Suisse; 2005 Jan; 1(3):249-50, 252-5. PubMed ID: 15770820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion.
    Mortensen C; Karlsen S; Grønbæk H; Nielsen DT; Frevert S; Clemmesen JO; Møller S; Jensen JS; Bendtsen F
    Liver Int; 2013 Oct; 33(9):1309-15. PubMed ID: 23763259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventing first variceal hemorrhage in cirrhosis.
    Albillos A
    J Clin Gastroenterol; 2007; 41 Suppl 3():S305-11. PubMed ID: 17975481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of transjugular intrahepatic portosystemic shunt for variceal bleeding in hepatocellular carcinoma patients with portal vein thrombosis].
    Chung WJ; Jang BK; Park KS; Cho KB; Hwang JS; Ahn SH; Kim YH; Kim YH; Kim YJ
    Korean J Hepatol; 2005 Jun; 11(2):157-63. PubMed ID: 15980674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension.
    La Mura V; Abraldes JG; Raffa S; Retto O; Berzigotti A; García-Pagán JC; Bosch J
    J Hepatol; 2009 Aug; 51(2):279-87. PubMed ID: 19501930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with cirrhosis and bare-stent TIPS may have increased risk of hepatocellular carcinoma.
    Bañares R; Núñez O; Escudero M; Fernández C; Vaquero J; Beceiro I; Echenagusía A; Clemente G; Santos L
    Hepatology; 2005 Mar; 41(3):566-71. PubMed ID: 15726654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic response-guided therapy for prevention of variceal rebleeding: an uncontrolled pilot study.
    González A; Augustin S; Pérez M; Dot J; Saperas E; Tomasello A; Segarra A; Armengol JR; Malagelada JR; Esteban R; Guardia J; Genescà J
    Hepatology; 2006 Oct; 44(4):806-12. PubMed ID: 17006916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Strategies for the prevention of hepatocellular carcinoma in the context of chronic viral hepatitis].
    Schott E; Bergk A; Berg T
    Z Gastroenterol; 2008 Jan; 46(1):69-80. PubMed ID: 18188819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver cirrhosis.
    Pinzani M; Rosselli M; Zuckermann M
    Best Pract Res Clin Gastroenterol; 2011 Apr; 25(2):281-90. PubMed ID: 21497745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma?
    Tanaka K; Sata M; Uchimura Y; Suzuki H; Tanikawa K
    Oncol Rep; 1998; 5(1):205-8. PubMed ID: 9458323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
    Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
    Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does antiviral therapy prevent hepatocellular carcinoma?
    Kwon H; Lok AS
    Antivir Ther; 2011; 16(6):787-95. PubMed ID: 21900710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Surgical approach to posthepatitic cirrhotic patient today].
    Meriggi F; Forni E
    G Chir; 1996; 17(6-7):370-8. PubMed ID: 9272983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
    Marotta F; Vangieri B; Cecere A; Gattoni A
    Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.